UCBJF:OTCMKTS
UCB SA
235,94 $
0,00%
(0,00) 1 p
13. okt, 10:35:17 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse UCBJF põhistatistika genereerimine…
Turu kapit.
37,35 mld
Keskm. maht
142,00
Maht
180,00
52 näd kõrgeim
345,39 $
52 näd madalaim
219,60 $
Beeta
0,58
Käibivad aktsiad
194,51 mln
Töötajate arv
9 tuh
Turu kapit.
37,35 mld
Keskm. maht
142,00
Maht
180,00
52 näd kõrgeim
345,39 $
52 näd madalaim
219,60 $
Beeta
0,58
Käibivad aktsiad
194,51 mln
Töötajate arv
9 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
ad-hoc-news.de
·
17 tunni eest
UCB dedicates Georgia site. UCB stock sits 30.78 percent below its high
ad-hoc-news.de
·
20 tunni eest
UCB launches Wear It Out program: UCB stock pre-market at EUR 198.60
ad-hoc-news.de
·
1 päeva eest
ING sets EUR 304.00 target for UCB stock with 48.87 percent upside
ad-hoc-news.de
·
1 päeva eest
UCB presented Bimzelx data. UCB stock loses 1.06 percent.??
Profiil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Teave üksuse UCB SA kohta
TegevjuhtJean-Christophe Tellier
Töötajad9 tuh
Asutatud18. jaan 1928
Peakontorid-
Sektor-
Veebisaitucb.com